Steven Hatfill promoveu uso do medicamento contra malária para tratar Covid-19 mesmo sem evidências de eficácia

Trump chooses chloroquina defender to take up US management against pandemics

Pfizer Japan said on April 28 that it has filed its oral COVID-19 treatment Paxlovid (nirmatrelvir/ritonavir) for a wider label to include its use in children six years of age and older who weigh at least 20 kg.

Paxlovid Filed for Pediatric Label Expansion in Japan: Pfizer

Novel Mpro inhibitors exhibit broad activity against SARS-CoV-2 and other coronaviruses.

New antiviral compounds show broad protection against COVID-19 variants

Models found no difference in all-cause death rates, 30-day hospital readmissions, or length of stay before and after restrictions were put into place.

COVID patients who don't receive remdesivir not more likely to die, data suggest

A team at UC San Francisco and Gladstone Institutes has developed new drug candidates that show great promise against the virus that causes COVID-19 and potentially other coronaviruses that could cause future pandemics.

antiviral news

Press Releases in the global landscape